| | |
|---|---|
| **Statistical analysis title** | Cohort 1, ACP: Fesoterodine 4 mg |
| Statistical analysis description | P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline detrusor pressure at maximum bladder capacity and baseline weight. |
| Comparison groups | Cohort 1, Active Comparator Phase: Fesoterodine 4 mg |
| Number of subjects included in analysis | 40 |
| Analysis specification | Pre-specified |
| Analysis type | Superiority |
| P-value | = 0.2334 |
| Method | ANCOVA |
| Confidence interval | |
| **Statistical analysis title** | Cohort 1, ACP: Fesoterodine 8 mg |
| Statistical analysis description | P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline detrusor pressure at maximum bladder capacity and baseline weight. |
| Comparison groups | Cohort 1, Active Comparator Phase: Fesoterodine 8 mg |

| | |
|---|---|
| Number of subjects included in analysis | 41 |
| Analysis specification | Pre-specified |
| Analysis type | Superiority |
| P-value | = 0.5087 |
| Method | ANCOVA |
| Confidence interval | |
| **Statistical analysis title** | Cohort 1, ACP: Oxybutynin |
| Statistical analysis description | P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline detrusor pressure at maximum bladder capacity and baseline weight. |
| Comparison groups | Cohort 1, Active Comparator Phase: Oxybutynin |
| Number of subjects included in analysis | 38 |
| Analysis specification | Pre-specified |
| Analysis type | Superiority |
| P-value | = 0.3333 |

| Method | ANCOVA |
|---|---|
| Confidence interval | |